Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
1249.30Today’s High
1292.8052W low
647.6052W High
1292.80Open Price
1251.80Prev. Close
1209.8500Volume
1421833.00Value
1822505539.40Fundamentals
Market Cap Cr
36170.90
Price to Earnings
-22.20
Price to Book Value
4.60
Dividend Yield
0.20
PE to Growth
0.00
Op Revenue TTM Cr
12178.63
Net Profit TTM Cr
-1628.41
Cash From Operating Activity Cr
-265.44
Return on Equity %
-19.13
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
03 Jul, 2024
32.8
Week
41.4
Month
40.8
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
1274.63
PIVOT
First Resistance
1299.97
Second Resistance
1318.13
Third Resistance
1343.47
First Support
1256.47
Second Support
1231.13
Third Support
1212.97
Relative Strength Index
68.4
Money Flow Index
69.06
MACD
36.87
MACD Signal
38.19
Average True Range
35.71
Average Directional Index
20.72
Rate of Change (21)
8.98
Rate of Change (125)
49.8
Commodity Channel Index
166.4
Williams %R
-11.6
BETA
1 Month
0.81
3 Month
0.73
1 Year
0.79
3 Year
0.24
PRICE CHANGE ANALYSIS
↑ 5.64%
1 Week
Low
High
1199.3
1292.8
↑ 10.47%
1 Month
Low
High
1037.15
1292.8
↑ 29.87%
3 Months
Low
High
978.95
1292.8
↑ 44.22%
6 Months
Low
High
771
1292.8
↑ 89.62%
1 Year
Low
High
647.65
1292.8
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 2934.49 | 1623.91 | 2279.63 | 2193.74 | 2172.01 | 2251.20 | 2524.94 | 2258.45 | 1964.53 | 2249.80 | 2261.56 | |
| Operating Expenses Qtr | 1650.78 | 1549.36 | 1762.57 | 1659.39 | 1721.38 | 1722.63 | 1825.78 | 1478.11 | 1623.96 | 1522.57 | 1721.36 | |
| Operating Profit Qtr | 497.45 | -184.27 | 470.85 | 485.00 | 217.67 | 438.84 | 382.43 | 433.82 | 161.59 | 510.48 | 459.51 | |
| EBIDT Qtr Cr | 6430.63 | 49.26 | 497.40 | 502.73 | -207.74 | 691.07 | 699.16 | 780.34 | 340.57 | 727.23 | 970.53 | |
| Depreciation Qtr | 52.40 | 51.16 | 49.85 | 48.75 | 46.73 | 46.22 | 46.17 | 45.03 | 41.77 | 40.80 | 39.68 | |
| Net Profit Qtr | 4613.69 | -20.41 | 302.35 | 271.66 | -137.47 | 430.50 | 423.15 | 492.58 | 205.60 | 548.52 | 754.26 | |
| Basic EPS Qtr | 163.50 | -0.72 | 10.72 | 9.63 | -4.87 | 15.26 | 15.00 | 17.46 | 7.29 | 19.44 | 26.73 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 9059.14 | 9206.60 | 8756.21 | 7964.17 | 7319.42 | |
| Operating Expenses Annual Cr | 6649.46 | 6747.90 | 6453.36 | 5677.59 | 5408.40 | |
| Operating Profit Annual | 1241.66 | 1472.77 | 1688.22 | 1890.34 | 1304.23 | |
| Operating Profit Margin Annual % | 13.71 | 16.00 | 19.28 | 23.74 | 17.82 | |
| Total Expenses Annual Cr | 7128.73 | 7138.86 | 6849.10 | 6094.31 | 5803.33 | |
| EBIDT Annual Cr | 2409.69 | 2458.71 | 2302.85 | 2286.58 | 1911.02 | |
| EBIDT Annual margin % | 26.60 | 26.71 | 26.30 | 28.71 | 26.11 | |
| Depreciation | 202.16 | 184.15 | 159.69 | 150.81 | 138.54 | |
| PAT Before ExtraOrdinary Items Annual Cr | 5167.29 | 1208.77 | 1997.79 | 1649.45 | 1354.55 | |
| Net Profit Annual | 5167.29 | 1208.77 | 1997.79 | 1649.45 | 1354.55 | |
| Basic EPS Annual | 183.13 | 42.84 | 70.80 | 58.46 | 48.00 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 22970.62 | 17877.46 | 16738.59 | 14809.51 | 13226.26 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 154.39 | 3066.69 | 2734.84 | 3304.67 | 3336.82 | |
| Total Current Liabilities Annual Cr | 4289.39 | 3641.77 | 3441.06 | 2503.35 | 2388.52 | |
| Total Capital Plus Liabilities Annual Cr | 27414.39 | 24585.92 | 22914.48 | 20617.52 | 18951.60 | |
| Fixed Assets Annual | 1953.91 | 1918.28 | 1861.37 | 1853.89 | 1811.96 | |
| Total Non Current Assets Annual | 22732.92 | 20200.75 | 18511.56 | 15708.40 | 14527.70 | |
| Total Current Assets Annual | 4681.47 | 4385.18 | 4402.93 | 4909.12 | 4423.90 | |
| Total Assets Annual | 27414.39 | 24585.92 | 22914.48 | 20617.52 | 18951.60 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 3922.95 | 3699.68 | 4012.99 | 4663.26 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | -495.45 | 1474.06 | 1216.07 | 1243.42 | 1579.12 | |
| Cash from Investing Activity Annual | 3197.19 | -431.47 | -896.92 | -1235.23 | -1607.38 | |
| Cash from Financing Annual Activity | -2666.45 | -978.50 | -305.12 | -80.79 | -139.42 | |
| Net Cash Flow Annual | - | 64.10 | 14.03 | -72.61 | -167.68 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 814.01 | 633.57 | 593.21 | 524.84 | 468.73 | |
| ROE Annual % | 22.49 | 6.76 | 11.93 | 11.13 | 10.24 | |
| ROCE Annual % | 9.54 | 10.86 | 11.00 | 11.79 | 10.70 | |
| Total Debt to Total Equity Annual | 0.03 | 0.18 | 0.22 | 0.24 | 0.27 | |
| EBDIT Annual Margin % | 30.53 | 29.90 | 28.28 | 30.21 | 28.46 |
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 3836.12 | 2552.11 | 3209.07 | 3422.47 | 3333.50 | 3540.27 | 3472.68 | 2960.44 | 3126.35 | 3187.31 | 3134.38 | |
| Operating Expenses Qtr | 2558.61 | 2715.35 | 2745.09 | 2770.39 | 2768.75 | 2843.61 | 2753.69 | 2345.69 | 2555.75 | 2480.26 | 2557.28 | |
| Operating Profit Qtr | 504.34 | -208.65 | 462.29 | 631.21 | 604.97 | 620.24 | 621.56 | 431.60 | 463.40 | 693.15 | 590.17 | |
| EBIDT Qtr Cr | 855.10 | -121.20 | 257.30 | 600.06 | -234.98 | 730.54 | 718.99 | 614.76 | 488.07 | 528.67 | 577.10 | |
| Depreciation Qtr | 151.34 | 147.07 | 141.45 | 154.65 | 146.53 | 162.28 | 155.71 | 146.75 | 131.52 | 118.93 | 123.19 | |
| Net Profit Qtr | -1218.28 | -351.38 | -81.94 | 23.19 | -428.30 | 290.76 | 260.44 | 192.53 | 155.59 | 221.90 | 274.81 | |
| Basic EPS Qtr | -43.18 | -12.45 | -2.90 | 5.31 | -15.18 | 9.66 | 9.23 | 6.82 | 5.51 | 7.86 | 9.74 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 12653.09 | 13306.90 | 12471.58 | 10994.15 | 10800.57 | |
| Operating Expenses Annual Cr | 10617.77 | 10711.74 | 9984.60 | 8859.55 | 8942.89 | |
| Operating Profit Annual | 1195.33 | 2278.37 | 2320.30 | 2084.38 | 1698.08 | |
| Operating Profit Margin Annual % | 9.45 | 17.12 | 18.60 | 18.96 | 15.72 | |
| Total Expenses Annual Cr | 11715.64 | 11672.59 | 10769.42 | 9656.22 | 9737.37 | |
| EBIDT Annual Cr | 2035.33 | 2595.16 | 2486.97 | 2134.60 | 1857.68 | |
| EBIDT Annual margin % | 16.09 | 19.50 | 19.94 | 19.42 | 17.20 | |
| Depreciation | 581.91 | 611.27 | 486.71 | 443.55 | 417.17 | |
| PAT Before ExtraOrdinary Items Annual Cr | -1830.85 | 377.40 | 993.65 | 970.09 | 775.97 | |
| Net Profit Annual | -1501.67 | 297.25 | 941.71 | 970.04 | 775.97 | |
| Basic EPS Annual | -53.22 | 10.53 | 33.37 | 34.38 | 27.50 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 7847.93 | 9473.92 | 9086.65 | 7064.63 | 6070.51 | |
| Minority Interest Liability Annual Cr | -0.38 | 365.34 | 351.47 | -0.35 | -0.39 | |
| Total Non Current Liabilities Annual Cr | 692.49 | 4486.89 | 2955.74 | 4338.28 | 4488.71 | |
| Total Current Liabilities Annual Cr | 5818.59 | 5045.53 | 4689.43 | 4201.02 | 4125.98 | |
| Total Capital Plus Liabilities Annual Cr | 14358.62 | 19371.68 | 17083.29 | 15603.58 | 14684.81 | |
| Fixed Assets Annual | 4804.68 | 7380.02 | 6837.10 | 6452.51 | 6197.54 | |
| Total Non Current Assets Annual | 6930.54 | 9497.96 | 8800.94 | 8244.00 | 7881.19 | |
| Total Current Assets Annual | 7428.08 | 9873.72 | 8282.35 | 7359.58 | 6803.62 | |
| Total Assets Annual | 14358.62 | 19371.68 | 17083.29 | 15603.58 | 14684.81 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 477.58 | 559.75 | 544.81 | 437.37 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | -265.44 | 625.39 | 1108.65 | 1131.21 | 1392.41 | |
| Cash from Investing Activity Annual | 4369.14 | -528.49 | -333.28 | -675.24 | -783.52 | |
| Cash from Financing Annual Activity | -3906.13 | -77.46 | -520.49 | -441.78 | -444.66 | |
| Net Cash Flow Annual | - | 19.45 | 254.88 | 14.20 | 164.23 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 278.09 | 348.70 | 334.48 | 250.36 | 215.12 | |
| ROE Annual % | -19.13 | 3.13 | 10.36 | 13.73 | 12.78 | |
| ROCE Annual % | 17.01 | 13.84 | 16.13 | 14.83 | 13.64 | |
| Total Debt to Total Equity Annual | 0.13 | 0.46 | 0.40 | 0.66 | 0.74 | |
| EBDIT Annual Margin % | 17.22 | 19.97 | 20.21 | 19.50 | 17.45 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| HDFC MUTUAL FUND - HDFC MID-CAP OPPORTUNITIES FUND | 2.54 | 74553156 | - | - |
| ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C | 2.06 | 74553157 | - | - |
| ICICI PRUDENTIAL MNC FUND | 1.23 | 74553158 | - | - |
| SMALLCAP WORLD FUND, INC | 3.47 | 74553164 | - | - |
| GOVERNMENT PENSION FUND GLOBAL | 3.14 | 74553165 | - | - |
| ASHISH DHAWAN | 2.55 | 74553175 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| SALDANHA FAMILY TRUST | 45.45 | 74553153 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| HDFC MUTUAL FUND - HDFC MID-CAP OPPORTUNITIES FUND | 2.54 | 74553156 |
| ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C | 2.06 | 74553157 |
| ICICI PRUDENTIAL MNC FUND | 1.23 | 74553158 |
| SMALLCAP WORLD FUND, INC | 3.47 | 74553164 |
| GOVERNMENT PENSION FUND GLOBAL | 3.14 | 74553165 |
| ELLIPSIS PARTNERS LLC | 1.68 | 74553166 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| ASHISH DHAWAN | 2.55 | 74553175 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Sep 18, 2023 | 2.5 | FINAL | - | Equity Share |
| Sep 12, 2022 | 2.5 | FINAL | - | Equity Share |
| Sep 08, 2021 | 2.5 | FINAL | - | Equity Share |
| Sep 17, 2020 | 2.5 | FINAL | - | Equity Share |
| Sep 19, 2019 | 2 | FINAL | - | Equity Share |
| Sep 19, 2018 | 2 | FINAL | - | Equity Share |
| Sep 20, 2017 | 2 | FINAL | - | Equity Share |
| Aug 03, 2016 | 2 | FINAL | - | Equity Share |
| Sep 10, 2015 | 2 | FINAL | - | Equity Share |
| Jul 10, 2014 | 2 | FINAL | - | Equity Share |
| Jul 18, 2013 | 2 | FINAL | - | Equity Share |
| Jul 19, 2012 | 2 | FINAL | - | Equity Share |
| Jul 28, 2011 | 0.4 | FINAL | - | Equity Share |
| Sep 16, 2010 | 0.4 | FINAL | - | Equity Share |
| Sep 10, 2009 | 0.4 | FINAL | - | Equity Share |
| Nov 07, 2007 | 0.7 | INTERIM | Nov 08, 2007 | Equity Share |
| Jan 04, 2007 | 0.8 | INTERIM | Jan 05, 2007 | Equity Share |
| Feb 07, 2006 | 0.7 | INTERIM | Feb 09, 2006 | Equity Share |
| Apr 29, 2005 | 0.7 | INTERIM | May 02, 2005 | Equity Share |
| Mar 31, 2004 | 1.3 | INTERIM | Apr 03, 2004 | Equity Share |
| Jun 10, 2003 | 6.5 | INTERIM | - | Equity Share |
| Sep 12, 2002 | 6 | FINAL | - | Equity Share |
| Sep 03, 2001 | 4 | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|---|---|
| Sep 10, 2007 | 2:1 | - |
| Oct 23, 2003 | 10:2 | 2003-10-31 |
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 24, 2024 | Audited Results & Final Dividend | - |
| Feb 14, 2024 | Quarterly Results | - |
| Nov 10, 2023 | Quarterly Results | - |
| Aug 11, 2023 | Quarterly Results | - |
| May 19, 2023 | Audited Results & Final Dividend | - |
| Feb 10, 2023 | Quarterly Results | - |
| Nov 11, 2022 | Quarterly Results | - |
| Aug 10, 2022 | Quarterly Results | - |
| May 27, 2022 | Audited Results & Final Dividend | - |
| Feb 11, 2022 | Quarterly Results | - |
| Nov 12, 2021 | Quarterly Results | - |
| Aug 13, 2021 | Quarterly Results | - |
| May 28, 2021 | Audited Results & Final Dividend | - |
| Feb 12, 2021 | Quarterly Results & Others | Inter alia, , to consider opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds, being, its U.S.$200 million |
| Nov 06, 2020 | Quarterly Results | - |
| Aug 14, 2020 | Quarterly Results | - |
| Jun 26, 2020 | Audited Results & Dividend | - |
| Feb 14, 2020 | Quarterly Results & Others | inter-alia, consider and evaluate proposals for raising of funds either by issuance of bonds / debentures / non-convertible debt instruments or any other securities or any combination thereof, |
| Nov 14, 2019 | Quarterly Results | - |
| Aug 13, 2019 | Quarterly Results | - |
| May 29, 2019 | Others | - |
| Feb 14, 2019 | Quarterly Results | - |
| Nov 13, 2018 | Quarterly Results | - |
| Sep 28, 2018 | Others | To consider opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds. |
| Aug 10, 2018 | Quarterly Results | - |
| May 29, 2018 | Audited Results & Dividend | - |
| Feb 08, 2018 | Quarterly Results | - |
| Nov 02, 2017 | Quarterly Results | - |
| Jul 27, 2017 | Quarterly Results | - |
| May 11, 2017 | Audited Results | - |
| Feb 02, 2017 | Quarterly Results | - |
| Oct 27, 2016 | Quarterly Results | - |
| Aug 12, 2016 | Quarterly Results | - |
| May 12, 2016 | Audited Results & Dividend | - |
| Jan 28, 2016 | Quarterly Results | - |
| Oct 29, 2015 | Quarterly Results | - |
| Jul 30, 2015 | Quarterly Results | - |
| May 29, 2015 | Audited Results & Dividend | - |
| Feb 12, 2015 | Quarterly Results | - |
| Oct 30, 2014 | Quarterly Results | - |
| Jul 24, 2014 | Quarterly Results | - |
| May 08, 2014 | Audited Results & Dividend | - |
| Jan 24, 2014 | Quarterly Results | - |
| Oct 31, 2013 | Quarterly Results | - |
| Aug 01, 2013 | Quarterly Results | - |
| May 07, 2013 | Audited Results & Dividend | - |
| Jan 29, 2013 | Quarterly Results | - |
| Oct 30, 2012 | Quarterly Results | - |
| Aug 02, 2012 | Quarterly Results | - |
| May 08, 2012 | Audited Results, Dividend & ESOP | Employees Stock Option Plan. |
| Jan 30, 2012 | Quarterly Results | - |
| Nov 09, 2011 | Quarterly Results | - |
| Jul 26, 2011 | Quarterly Results | - |
| May 10, 2011 | Audited Results & Dividend | - |
| Feb 01, 2011 | Quarterly Results | - |
| Oct 27, 2010 | Quarterly Results | - |
| Aug 24, 2010 | Allotment of Shares | The Board has allotted 38,000 Shares to the Employees of the Company on exercise of options granted to them pursuant to ESOS 2003. |
| Jul 27, 2010 | Quarterly Results | - |
| May 28, 2010 | Audited Results & Dividend | - |
| Jan 29, 2010 | Quarterly Results & ESOP | The Board has allotted 59,200 Shares to the Employees of the Company on exercise of options granted to them pursuant to ESOS 2003. |
| Oct 29, 2009 | Quarterly Results & Others | The Board has approved the conversion of 64,100 stock options issued to its Employees into 64,100 Equity Shares pursuant to the ESOS 2003. |
| Aug 14, 2009 | Appointment of Additional Director's | The Board appointed Mr. D R Mehta & Mrs. B E Saldanha as Additional Director of the Company. |
| Jul 27, 2009 | Quarterly Results & Others | To raise the funds through issue of Equity Shares /GDRs/ADRs/FCCBs & / or such other securities for an amt. not exceeding US$ 250 million & to convert 84,000 stock options issued to its employees. |
| Jun 26, 2009 | Audited Results, Dividend & Others | Inter alia, to allot 25,800 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003. |
| Apr 17, 2009 | Allotment of Shares to the Employees | Inter alia, to allot 7,000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003. |
| Jan 27, 2009 | Quarterly Results | - |
| Oct 27, 2008 | Quarterly Results | - |
| Aug 11, 2008 | Employees Stock Option Plan | To allot 1,000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003. |
| Jul 28, 2008 | Quarterly Results & Others | To allot 81,100 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003. |
| Apr 28, 2008 | Audited Results | - |
| Jan 21, 2008 | Quarterly Results | - |
| Oct 31, 2007 | Quarterly Results & Interim Dividend | - |
| Jul 30, 2007 | Quarterly Results | - |
| Jun 11, 2007 | Stock Split | - |
| Apr 25, 2007 | Audited Results | - |
| Jan 23, 2007 | Quarterly Results | - |
| Dec 26, 2006 | Interim Dividend | - |
| Oct 31, 2006 | Quarterly Results | - |
| Jul 31, 2006 | Quarterly Results | - |
| Apr 28, 2006 | Accounts | - |
| Jan 31, 2006 | Quarterly Results & Interim Dividend | - |
| Oct 31, 2005 | Quarterly Results | - |
| Jul 29, 2005 | Quarterly Results | - |
| Jul 04, 2005 | Employees Stock Option Plan | were converted into 10,000 Equity shares to the employees of the Company. |
| Apr 27, 2005 | Quarterly Results | - |
| Apr 26, 2005 | Interim Dividend | - |
| Mar 18, 2005 | Allotment of Bonus Shares | - |
| Jan 27, 2005 | Quarterly Results | - |
| Jan 06, 2005 | Bonus issue | - |
| Dec 11, 2004 | Others | To consider issue of Foreign currency convertible bonds. |
| Oct 25, 2004 | Quarterly Results | - |
| Jul 22, 2004 | Quarterly Results | - |
| Apr 22, 2004 | Quarterly Results | - |
| Mar 29, 2004 | Interim Dividend | To consider Investment in India & abroad |
| Jan 31, 2004 | Quarterly Results | - |
| Oct 24, 2003 | Quarterly Results | - |
| Sep 29, 2003 | Others | To consider and approve the conversion of Debentures issued to CDC Financial Services (Mauritius) Ltd. and South Asia Regional Fund into equity shares. |
| Jul 31, 2003 | Quarterly Results | - |
| May 16, 2003 | Accounts & Final Dividend | - |
| May 15, 2003 | Interim Dividend | - |
| Mar 25, 2003 | Interim Dividend on Pref. Shares | - |
| Feb 14, 2003 | Others | To consider divesting its wholly-owned subsidiary Glenmark Laboratories Ltd. including sale of its manufacturing plant at Verna, Goa. |
| Jan 17, 2003 | Quarterly Results | - |
| Oct 25, 2002 | Quarterly Results | - |
| Aug 06, 2002 | Others | To consider the creation of a mortgage securing the conversion & payment of interest in respect of the said FCD and to appoint UTI Bank to act as the Debenture Trustee in respect of the same. |
| Jul 30, 2002 | Quarterly Results | - |
| Jul 04, 2002 | Others | 1.To ratify the agreement entered into by the company with CDC Financial Services (Mauritius) Ltd., 2. Issue of FCDs for of Rs.50 crores on private placement basis 3. Replacing AoA of the company. |
| May 16, 2002 | Accounts & Dividend | - |
| Mar 09, 2002 | Interim Dividend | - |
| Jan 28, 2002 | Quarterly Results | - |
| Oct 29, 2001 | Half Yearly Results | - |
| Jul 30, 2001 | Quarterly Results | - |
| May 18, 2001 | Accounts & Dividend | - |
| Jan 16, 2001 | Quarterly Results | - |
| Oct 24, 2000 | Half Yearly Results | - |
| Jul 26, 2000 | Quarterly Results | - |
| May 15, 2000 | Accounts & Merger | - |
| Mar 10, 2000 | Dividend-Interim | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
| Mar 04, 2005 | 1:1 | - |
12 Jun 2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed - Release Capsules USP, 20 mg (OTC)
04 Jun 2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Transcript Of Investor Day 2024
The transcript of Investor Day 2024 held on Thursday, May 30, 2024 has been uploaded on Company''s website.
31 May 2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Audio Recording Of The Glenmark Pharmaceuticals Limited - Investor Day 2024
Audio Recording of Investor Day 2024 held on 30th May, 2024
30 May 2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation
Further to our communication dated 17th May, 2024, attached is the copy of the presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2024 which is scheduled today in Mumbai.
29 May 2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
The transcript of the Earnings Call held on May 27, 2024 has been uploaded on the Company''s website.
28 May 2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the financial year 2023-24
28 May 2024
Glenmark Pharma Q4 Results Review - Operating Performance Above Estimate; FY25 Outlook Better: Motilal Oswal
Adverse market dynamics/de-prioritisation of intangibles lead to an impairment of Rs 23 billion
27 May 2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q4 2023-24 Earnings call held on 27th May 2024, on the website of the Company
27 May 2024
Glenmark Pharmaceuticals Results Earnings Call for Q4FY24
Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
25 May 2024
Glenmark Pharmaceuticals plans Rs 700 Crores CAPEX in FY25 to boost growth
Glenmark has earmarked Rs 700 crores for consolidated capital expenditures (CAPEX) to bolster its operational infrastructure. This allocation will be used to augment the company's capabilities to meet growing demand efficiently and sustain long-term growth.
